JP2016536369A - 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 - Google Patents

抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 Download PDF

Info

Publication number
JP2016536369A
JP2016536369A JP2016552455A JP2016552455A JP2016536369A JP 2016536369 A JP2016536369 A JP 2016536369A JP 2016552455 A JP2016552455 A JP 2016552455A JP 2016552455 A JP2016552455 A JP 2016552455A JP 2016536369 A JP2016536369 A JP 2016536369A
Authority
JP
Japan
Prior art keywords
doses
days
dose
interval
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016552455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536369A5 (enExample
Inventor
トーマス ホーマン
トーマス ホーマン
ジャネット チータム
ジャネット チータム
スコット ホイットカップ
スコット ホイットカップ
エリック リッパ
エリック リッパ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2016536369A publication Critical patent/JP2016536369A/ja
Publication of JP2016536369A5 publication Critical patent/JP2016536369A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016552455A 2013-11-05 2014-11-04 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法 Pending JP2016536369A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361900246P 2013-11-05 2013-11-05
US61/900,246 2013-11-05
US201462016620P 2014-06-24 2014-06-24
US62/016,620 2014-06-24
PCT/US2014/063951 WO2015069668A1 (en) 2013-11-05 2014-11-04 Method of treating conditions of the eye with an anti-vegf darpin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020106978A Division JP2020169191A (ja) 2013-11-05 2020-06-22 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法

Publications (2)

Publication Number Publication Date
JP2016536369A true JP2016536369A (ja) 2016-11-24
JP2016536369A5 JP2016536369A5 (enExample) 2018-02-22

Family

ID=51947485

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016552455A Pending JP2016536369A (ja) 2013-11-05 2014-11-04 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法
JP2020106978A Pending JP2020169191A (ja) 2013-11-05 2020-06-22 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法
JP2022076645A Pending JP2022107628A (ja) 2013-11-05 2022-05-06 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020106978A Pending JP2020169191A (ja) 2013-11-05 2020-06-22 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法
JP2022076645A Pending JP2022107628A (ja) 2013-11-05 2022-05-06 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法

Country Status (14)

Country Link
US (4) US20150126458A1 (enExample)
EP (2) EP3628324A1 (enExample)
JP (3) JP2016536369A (enExample)
KR (1) KR20160070164A (enExample)
CN (1) CN105960247A (enExample)
AU (2) AU2014346921A1 (enExample)
CA (1) CA2927012A1 (enExample)
DK (1) DK3065761T3 (enExample)
ES (1) ES2773317T3 (enExample)
HU (1) HUE047910T2 (enExample)
PL (1) PL3065761T3 (enExample)
PT (1) PT3065761T (enExample)
TW (1) TWI729970B (enExample)
WO (1) WO2015069668A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
MX363351B (es) 2011-10-13 2019-03-20 Aerpio Therapeutics Inc Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
CA3139164A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2022073072A1 (en) * 2020-10-07 2022-04-14 Implicit Bioscience Limited Methods and agents for the treatment of ocular disease
KR20230083299A (ko) 2020-10-08 2023-06-09 노탈 비전 엘티디. Oct 가이드 치료
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
CN114075290B (zh) * 2022-01-20 2022-04-19 南京鼓楼医院 Cd40靶向结合蛋白、其编码核酸以及用途
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN121910909B (zh) * 2026-03-27 2026-06-12 中国医学科学院病原生物学研究所 工程化多肽注射系统及其在靶向递送抗菌肽中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507271A (ja) * 2008-11-03 2012-03-29 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
JP2013531616A (ja) * 2010-04-30 2013-08-08 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプターの相互作用を阻害する改変結合タンパク質

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CA2644712C (en) 2006-03-06 2016-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
EP2111228B1 (en) 2007-02-02 2011-07-20 Bristol-Myers Squibb Company 10Fn3 domain for use in treating diseases associated with inappropriate angiogenesis
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
PT2846836T (pt) * 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507271A (ja) * 2008-11-03 2012-03-29 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプター相互作用を阻害する結合タンパク質
JP2013531616A (ja) * 2010-04-30 2013-08-08 モレキュラー・パートナーズ・アーゲー Ｖｅｇｆ−ａレセプターの相互作用を阻害する改変結合タンパク質

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AM J OPHTALMOL, vol. 155, no. 4, JPN6018032493, April 2013 (2013-04-01), pages 697 - 704, ISSN: 0004216840 *
ARVO ANNUAL MEETING ABSTRACT SEARCH AND PROGRAM PLANNER, vol. 2011, JPN6018032496, 2011, pages 1655, ISSN: 0004216842 *
PUBMED ABSTRACT PMID:15523197, JPN6019014301, 2006, ISSN: 0004021616 *
プラクティス, vol. 29, no. 2, JPN6018032495, 2012, pages 132 - 133, ISSN: 0004216841 *

Also Published As

Publication number Publication date
US20210008158A1 (en) 2021-01-14
US20150126458A1 (en) 2015-05-07
JP2022107628A (ja) 2022-07-22
WO2015069668A1 (en) 2015-05-14
US20170157207A1 (en) 2017-06-08
PL3065761T3 (pl) 2020-05-18
CA2927012A1 (en) 2015-05-14
CN105960247A (zh) 2016-09-21
KR20160070164A (ko) 2016-06-17
DK3065761T3 (da) 2020-02-17
US20220175881A1 (en) 2022-06-09
TW201609125A (zh) 2016-03-16
PT3065761T (pt) 2020-02-21
ES2773317T3 (es) 2020-07-10
TWI729970B (zh) 2021-06-11
HUE047910T2 (hu) 2020-05-28
AU2020202968A1 (en) 2020-05-21
JP2020169191A (ja) 2020-10-15
EP3065761A1 (en) 2016-09-14
EP3628324A1 (en) 2020-04-01
EP3065761B1 (en) 2020-01-08
AU2014346921A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
JP2022107628A (ja) 抗ｖｅｇｆ ｄａｒｐｉｎを用いた眼の容態の治療方法
US20220096596A1 (en) Method of treating amd in patients refractory to anti-vegf therapy
Zhang et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration
KR101698362B1 (ko) Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
CN103002920B (zh) 抑制vegf‑a受体相互作用的修饰结合蛋白
AU2016241499B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
US20230256107A1 (en) Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
TW201836646A (zh) 治療與血管生成及血管新生相關病症的方法
US20230054032A1 (en) Compositions and methods for treating ocular disease
CN116783299A (zh) 用于治疗视网膜疾病的双特异性适配体组合物
US11993649B2 (en) Antibodies against MFAP4
EP4454705A1 (en) Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and metaplasia of retinal pigment epithelium (rpe) cells
WO2025056713A1 (en) Egfr antagonists for the treatment of diseases involving unwanted migration, proliferation, and/or metaplasia of retinal pigment epithelium (rpe) cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200220